Advanced search
Start date
(Reference retrieved automatically from SciELO through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Evaluation of growth, laboratorial control and corticotherapy in a sample of patients with the classical form of 21-hydroxylase deficiency

Full text
Clarissa Cerchi A. Ramos [1] ; Lucas Ricci Bento [2] ; Ezequiel Moreira Gonçalves [3] ; Maricilda Palandi de Mello [4] ; Maria Tereza M. Baptista [5] ; Sofia Helena V. de Lemos-Marini [6] ; Gil Guerra-Júnior [7]
Total Authors: 7
[1] Universidade Estadual de Campinas. Faculdade de Ciências Médicas - Brasil
[2] Universidade Estadual de Campinas. Faculdade de Ciências Médicas - Brasil
[3] FCM - Brasil
[4] Centro de Biologia Molecular e Engenharia Genética da Unicamp - Brasil
[5] FCM. Departamento de Clínica Médica - Brasil
[6] Unicamp. Departamento de Pediatria - Brasil
[7] Unicamp. FCM. Departamento de Pediatria - Brasil
Total Affiliations: 7
Document type: Journal article
Source: Revista Paulista de Pediatria; v. 25, n. 4, p. 317-323, 2007-12-00.

OBJECTIVE: To verify the growth pattern of patients with congenital adrenal hyperplasia (CAH) due to classical 21hydroxylase (21-OH) deficiency in relation to hormonal control and use of corticoid during the treatment. METHODS: Retrospective analysis of data from 45 patients. The growth pattern was analyzed according to height gain or not, using the difference between height Z score (for bone age) at the last visit in relation to the height Z score (for chronological age) in the first visit. Concentrations of 17-OH progesterone (17-OHP), androstenedione and rennin were evaluated, and the patients were considered well-controlled when 50% or more of the dosages were normal. Corticoid therapy was analyzed according to type and dose. RESULTS: The age at last visit ranged from 2.8 to 26.6 years (12.6+5.8 years), 31 were females, 30 with salt wasting form; 62% were considered well-controlled for 17-OHP, 75% for androstenedione and 78% for renin. Hidrocortisone was used in 41 patients (20.2+2.6 mg/m²/day) and 40 in association with 9a-fludrocortisone. There were 14 patients with height gain, 20 with maintenance and 11 with loss. Height gain was associated with salt wasting patients (p=0.01) and with patients well-controlled for 17OHP (p=0,0005) and androstenedione (p=0,02). CONCLUSIONS: In this sample of patients with CAH due to classical 21-OH deficiency, better height gain was associated with a good control of 17-OHP and androstenedione and with salt wasting clinical form of the disease. (AU)

FAPESP's process: 06/01978-0 - Classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency: effect of hyperandrogenism in female proportion and composition
Grantee:Ezequiel Moreira Gonçalves
Support Opportunities: Scholarships in Brazil - Master